Biological Approaches to Aggressive Cutaneous B-Cell Lymphomas

Cicogna, Giulia Tadiotto; Ferranti, Martina; Lazzarotto, Annalisa; Alaibac, Mauro

doi:10.3389/fonc.2019.01238

Cited by 8 publications

(5 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multiagent chemotherapy should be reserved for patients developing extracutaneous disease or with widespread and nonresponsive skin lesions (45). PCDLBCL, LT should preferentially be treated as other diffuse large B-cell lymphoma, with CHOP-like regimens associated with rituximab and local radiotherapy (46)(47)(48). It is recommended that the patient is followed by a multidisciplinary team of experts in the management of these disorders for optimal treatment and careful follow-up.…”

Section: Discussionmentioning

confidence: 99%

Primary Cutaneous B-Cell Lymphomas: An Update

et al. 2020

View full text Add to dashboard Cite

Primary cutaneous B-cell lymphomas (PCBCLs) comprise a group of extranodal B-cell non-Hodgkin lymphomas B-cell derived, which primarily involve the skin without evidence of extracutaneous disease at the time of diagnosis. They include ∼25% of all cutaneous lymphomas and are classified in three major subgroups (World Health Organization (WHO) 2017): primary cutaneous marginal zone lymphoma (PCMZL), primary cutaneous follicle-center cell lymphoma (PCFCL), and diffuse large B-cell lymphoma, leg type (PCDLBCL, LT). This classification also includes some less common entities such as intravascular large B-cell lymphoma. Recently, WHO-EORTC added Epstein-Barr virus positive (EBV+) mucocutaneous ulcer, as a new provisional distinct entity, to cutaneous B-cell lymphomas. PCBCLs are classically characterized by patches, plaques, or nodules showing great variability for color, shape, and location. Diagnosis requires histological examination with immunohistochemical staining. In general, therapeutic options depend on the exact histological and immunohistochemical classification, disease presentation, and risk assessment. PCMZL and PCFCL are considered indolent lymphomas with a good prognosis and are associated with 5-year disease-specific survival ≥ 95%. In contrast, PCDLBCL, LT is considered an aggressive lymphoma with a survival rate in 5 years of lower than 60%. Patients with a solitary lesion or limited lesions in a single anatomical site require different treatments as compared to patients with generalized lesions or refractory disease or extracutaneous involvement. Therapeutic choice includes observation, local, or systemic therapy based on histology and disease extension. Patient management is multidisciplinary, including dermatologists, pathologists, hemato-oncologists, and radiation oncologists.

show abstract

Section: Discussionmentioning

confidence: 99%

Primary Cutaneous B-Cell Lymphomas: An Update

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Finally, a new generation of anti‐CD20‐Mab (ofatumumab, Y‐ibrutumab and I‐tositumomab), anti‐CD19‐Mab (tafasitamab), anti‐CD‐19 conjugates (loncastuximab), anti‐CD79 B conjugates (polatuzumab), anti‐CD40‐Mab (dacetuzumab), bispecific T‐cell engagers (blinatumomab) and CAR T‐cell therapy, which have been proven effective for nodal B‐cell lymphoma, might be applied in advanced PCBCL cases 83 …”

Section: Resultsmentioning

confidence: 99%

Identifying and addressing unmet clinical needs in primary cutaneous B‐cell lymphoma: A consensus‐based paper from an ad‐hoc international panel

Quaglino,

Pimpinelli,

Zinzani

et al. 2023

Hematological Oncology

View full text Add to dashboard Cite

Primary cutaneous B‐cell lymphomas (PCBCLs) are lymphoproliferative disorders that appear on the skin without evidence of extracutaneous manifestations at the time of diagnosis. There is a lack of evidence‐based guidelines for their clinical management due to the availability of very few large scale studies and controlled clinical trials. Here we present and discuss a series of major unmet clinical needs (UCNs) in the management of PCBCLs by a panel of 16 experts involved in research and clinical practice of PCBCL. The Panel produced recommendations on the appropriateness of the clinical decisions concerning the identified clinical needs and proposed research for improving the knowledge needed to solve them. Recommendations and proposals were achieved by multiple‐step formalized procedures to reach a consensus after a comprehensive analysis of the scientific literature. Recommendations and proposals lay in the domain of classification uncertainties of PCBCL, optimization of diagnosis, optimization of prognosis, optimization of staging and critical issues on therapeutic strategies with particular focus on new treatments. These recommendations are intended for use not only by experts but above all by dermatologists and hematologists with limited experience in the field of PCBCLs as well as general practitioners.

show abstract

“…The latter is an established target in B cell NHL owing to its expression in over 90% of malignant B cells [ 90 ]. However, some cases of B cell lymphoma (BCL) may show primary or secondary resistance to these targeted agents, motivating the research for alternative approaches and drug development strategies to bridge an unmet clinical need in the treatment of aggressive subtypes of BCL, including those primarily involving the skin [ 91 ].…”

Section: Antibody-directed Therapies For the Treatment Of Lymphomamentioning

confidence: 99%

Cutaneous Lymphoma and Antibody-Directed Therapies

et al. 2023

Self Cite

View full text Add to dashboard Cite

The introduction of monoclonal antibodies such as rituximab to the treatment of cancer has greatly advanced the treatment scenario in onco-hematology. However, the response to these agents may be limited by insufficient efficacy or resistance. Antibody–drug conjugates are an attractive strategy to deliver payloads of toxicity or radiation with high selectivity toward malignant targets and limited unwanted effects. Primary cutaneous lymphomas are a heterogeneous group of disorders and a current area of unmet need in dermato-oncology due to the limited options available for advanced cases. This review briefly summarizes our current understanding of T and B cell lymphomagenesis, with a focus on recognized molecular alterations that may provide investigative therapeutic targets. The authors reviewed antibody-directed therapies investigated in the setting of lymphoma: this term includes a broad spectrum of approaches, from antibody–drug conjugates such as brentuximab vedotin, to bi-specific antibodies, antibody combinations, antibody-conjugated nanotherapeutics, radioimmunotherapy and, finally, photoimmunotherapy with specific antibody–photoadsorber conjugates, as an attractive strategy in development for the future management of cutaneous lymphoma.

show abstract

Biological Approaches to Aggressive Cutaneous B-Cell Lymphomas

Cited by 8 publications

References 30 publications

Primary Cutaneous B-Cell Lymphomas: An Update

Primary Cutaneous B-Cell Lymphomas: An Update

Identifying and addressing unmet clinical needs in primary cutaneous B‐cell lymphoma: A consensus‐based paper from an ad‐hoc international panel

Cutaneous Lymphoma and Antibody-Directed Therapies

Contact Info

Product

Resources

About